BioWorld Asia

Feb. 16, 2011

View Archived Issues

European IPO Window Open? Philogen Files $89.6M Offering

Surface Alterations to Bacteria Affect Their Ability to Spread

Phase4 Ventures' Life Science Holdings Sold to HarbourVest

Medivir Inks Infectious Disease Pact with Janssen Pharmaceutica

Clavis Conducts Pancreatic Cancer Biomarker Study

Other News To Note

eTherapeutics Raises $33.6M, London's Invesco to Own 47.7%

LONDON – eTherapeutics plc achieved the seemingly impossible, raising £21 million (US$33.6 million) in a placment at a premium to the closing price on Monday, the day before the deal was announced. (BioWorld International) Read More

Renovo's Juvista Tanks in Phase III; Stock plunges 75%

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...